Receptor, Cannabinoid, CB1, antagonists & inhibitors
- Name
- Receptor, Cannabinoid, CB1, antagonists & inhibitors
- Accession Number
- DBCAT001661
- Description
Not Available
- Drugs
Drug Drug Description SLV319 Investigated for use/treatment in obesity. Rimonabant For use in conjunction with diet and exercise for patients with a body mass index greater than 30 kg/m2, or patients wih a BMI greater than 27 kg/m2 with associated... Ibipinabant Ibipinabant has been used in trials studying the treatment of Obesity and Obesity and Type 2 Diabetes. Surinabant Surinabant has been investigated for the treatment of Smoking Cessation. WIN 55212-2 WIN 55,212-2 is a chemical described as an aminoalkylindole derivative, which produces effects similar to those of cannabinoids such as tetrahydrocannabinol (THC) but has an entirely different chemical structure. It... Otenabant Otenabant has been investigated for the treatment of Obesity. - Drugs & Drug Targets
Drug Target Type SLV319 Cannabinoid receptor 1 target Rimonabant Cannabinoid receptor 1 target Rimonabant Cytochrome P450 3A4 enzyme Rimonabant G-protein coupled receptor 55 target WIN 55212-2 Cytochrome P450 3A4 enzyme Otenabant Cannabinoid receptor 1 target